Introduction
Materials and methods
Trial selection
Search strategy and quality assessment
Quality assessment
Outcome measures
Definitions
Statistical analysis
Results
Study | Year published | Reason for exclusion |
---|---|---|
Wagner and colleagues [78] | 1955 | Description of pneumonia therapy only with no severity stratification. Allocation by 'history number' |
Thompson and colleagues [79] | 1976 | Abstract; nine of 60 patients with cardiogenic shock; no subset analyses. Post-randomization exclusion of 4 patients |
Lucas and Ledgerwood [80] | 1984 | Open-label study; pseudo-randomization by hospital number |
VASSCS [81] | 1987 | Predominantly sepsis patients with no subgroup of shocked patients. No timing of fluid bolus with respect to reported hypotension |
Schattner and colleagues [82] | 1997 | pseudo-randomization of patients with 'early sepsis' |
Keh and colleagues [60] | 2003 | Cross-over placebo study in septic shock |
Confalonieri and colleagues [83] | 2005 | Community acquired pneumonia study; no subset analyses for shocked patients |
Rinaldi and colleagues [84] | 2006 | Post randomization exclusion of 15 patients; 3 with septic shock |
Huh and colleagues [85] | 2006 | Abstract; two hydrocortisone arms; no concurrent placebo arm reported |
Loisa and colleagues [86] | 2007 | Two hydrocortisone arms; no concurrent placebo group |
Nawab and colleagues [87] | 2007 | Abstract; severe community acquired pneumonia, no subset analysis; outcomes today-7 only |
Cicarelli and colleagues [88] | 2007 | Unspecified post-randomization exclusion of 'all patients who progressed to refractory septic shock' |
Kurugundla and colleagues [89] | 2008 | Abstract; ICU outcomes reported only |
Study | Year published | Year completed | Trial origin | Trial | Reported as Paper#/abstract | Design | Allocation concealment | Effect and sample size calculation | Early stopping | Sepsis/shock description | Predominant patient type | Primary outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cooperative Study Group [32] | 1963 | NA | USA | Multicenter | Paper | Double-blind | Yes | No | No | 'Life threatening infections' | Medical | Hospital mortality |
Klastersky and colleagues [41] | 1971 | 1970 | Belgium | Singlecenter | Paper | Double-blind | Yes | No | No | 'Life threatening infections' | Cancer | 30-day mortality |
Schumer [31] | 1976 | 1975 | USA | Singlecenter | Paper | Double-blind | NA | No | No | Septic history, falling blood pressure and positive blood cultures | Surgical | 28-day mortality |
Sprung and colleagues [43] | 1984 | 1982 | USA | Two-centers | Paper | Open-label | Yes | No | No | SBP < 90 mmHg, decreased organ perfusion hypotension despite fluid infusion, and bacteraemia or identified infection source | Medical | Hospital mortality |
Bone and colleagues [38] | 1987 | 1985 | USA | Multicenter | Paper | Double-blind | Yes | No | No | Evidence of infection, fever/hypothermia tachypnoea, inadequate organ perfusion/dysfunction, SBP < 90 mmHg/decrease 40 mmHg | Mixed | SS development ≤14 days post admission; reversal SS ≤14 days; death ≤14 days |
Luce and colleagues [46] | 1988 | 1986 | USA | Singlecenter | Paper | Double-blind | Yes | Yes | Yes | Fever/hypothermia, SBP < 90 mmHg, blood culture or body-fluid positive | Mixed | ARDS development, Hospital mortality |
Bollaert and colleagues [37] | 1998 | NA | France | Singlecenter | Paper | Double-blind | Yes | Yes | Yes | ACCP/SCCM criteria | Mixed | Shock-reversal |
Briegel and colleagues [39] | 1999 | 1996 | Germany | Singlecenter | Paper | Double-blind | Yes | Yes | No | ACCP/SCCM criteria | Mixed | Shock-reversal |
Chawla and colleagues [47] | 1999 | NA | USA | Singlecenter | Abstract | Double-blind | NA | NA | NA | NA | NA | Shock-reversal |
Yildiz and colleagues [45] | 2002 | 1999 | Turkey | Singlecenter | Paper | Double-blind | No | No | No | ACCP/SCCM criteria | Medical | 28-day mortality |
Annane and colleagues [36] | 2002 | 1999 | France | Multicenter | Paper | Double-blind | Yes | Yes | No | Documented evidence of infection; fever/hypothermia; SBP < 90 mmHg, despite fluid and vasopressors; decreased organ perfusion; mechanical ventilation | Mixed | 28-day survival distribution in corticorophin non-responders |
Tandan and colleagues [44] | 2005 | NA | India | Singlecenter | Abstract | Double-blind | NA | NA | NA | NA | 28-day mortality | |
Oppert and colleagues [ 42] | 2005 | NA | Germany | Singlecenter | Paper | Double-blind | Yes | NA | NA | Tachycardia; Fever/hypothermia; Positive culture; SBP < 90 mmHg with CVP ≥10 mmHg,; vasopressors | Medical | Time to vasopressor cessation |
Sprung and colleagues [8] | 2008 | 2005 | Europe | Multicenter | Paper | Double-blind | Yes | Yes | Yes | Clinical evidence of infection; evidence of systemic response to infection; shock (within 72 hours), SBP <90 mmHg despite fluid infusion or vasporessors; inadequate organ perfusion/dysfunction | Mixed | 28-day mortality in corticorophin non-responders |
Author | Quality score | Total N | Vasopressors atenrollment | Etomidate used | Steroid type | Steroid-days before tapering | Tapering days | Hydrocortisone equivalent (mg) | Age Steroid | Age Placebo | %males Steroid | %males Placebo |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cooperative Study Group [32] | 7 | 194 | NA | NA | Hydrocortisone | 1 | 2-6 | 1050 | NA | NA | 70.8 | 64.3 |
Klastersky and colleagues [41] | 7.5 | 85 | NA | NA | Betamethasone | 3 | None | 7000 | NA | NA | 60.1 | 46.2 |
Schumer [31] | 6 | 172 | NA | NA | Methyl-prednisolone | Bolus-day1 | None | 8050 | 49 | 51 | NA | NA |
Dexamethasone | Repeat unspecified | None | ||||||||||
Sprung and colleagues [43] | 8.5 | 59 | Yes (93%) | NA | Methyl-prednisolone | Bolus-day1 | None | 18884 | 56.5 | 48 | 83.7 | 62.5 |
Dexamethasone | Repeat in 74% | |||||||||||
Bone and colleagues [38] | 10 | 382 | NA | NA | Methyl-prednisolone | 4 doses in 24 hours | None | 42000 | 53 | 53.7 | NA | NA |
Luce and colleagues [46] | 11 | 75 | Yes (44%) | NA | Methyl-prednisolone | 4 doses in 24 hours | None | 42000 | 50 | 53 | 68.4 | 83.8 |
Bollaert and colleagues [37] | 13.5 | 41 | Yes | NA | Hydrocortisone | 5 | 6 | 2175 | 58.7 | 56.8 | 68.2 | 63.2 |
Briegel and colleagues [39] | 13.5 | 40 | Yes | NA | Hydrocortisone | 3 | 3-14 | 2126 | 47 | 51 | 45 | 60 |
Chawla and colleagues [47] | NA | 44 | Yes | NA | Hydrocortisone | 3 | 4 | 1350 | NA | NA | NA | NA |
Yildiz and colleagues [45] | 9 | 40 | NA | NA | Prednisolone | 10 | None | 300 | 57.8 | 56.5 | 65 | 55 |
Annane and colleagues [36] | 14.5 | 291 | Yes | Yes | Hydrocortisone | 7 | None | 1400 | 62 | 60 | 64 | 69.8 |
Tandan and colleagues [44] | NA | 28 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Oppert and colleagues [42] | 12.5 | 41 | Yes | Yes | Hydrocortisone | 2-3 | 2-5 | 856 | 59 | 47 | 72.2 | 82.6 |
Sprung and colleagues [8] | 14.5 | 499 | Yes (98.5%) | Yes | Hydrocortisone | 5 | 6 | 1800 | 63 | 63 | 66.1 | 67.8 |
Author | Mortality | Mortality | Shock-reversal | Shock-reversal | Corticotrophin | Corticotrophin | Shock-reversal | Shock-reversal | Shock-reversal | Shock-reversal | Superinfection | Superinfection | GIS bleed | GIS bleed | New | New |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospital | Hospital | days(7-28) | days(7-28) | responders | responders | responders | responders | non-responders | non-responders | hyperglycaemia | hyperglycaemia | |||||
n/total | n/total | n/total | n/total | Days (7-28) | Days (7-28) | Days (7-28) | Days (7-28) | |||||||||
Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | Steroid | Placebo | |
Cooperative StudyGroup [32] | 54/96 | 32/98 | NA | NA | 3/96 | 3/99 | 4/96 | 0/98 | NA | NA | ||||||
Klastersky and colleagues [41] | 24/66 | 18/39 | NA | NA | 11/46 | 6/39 | NA | NA | NA | NA | ||||||
Schumer [31] | 9/86 | 33/86 | NA | NA | 2/86 | 1/86 | 1/86 | 1/86 | ||||||||
Sprung and colleagues [43] | 33/43 | 11/16 | 25/43 | 6/16 | 11/43 | 1/16 | 1/43 | 2/32 | 4/45 | 0/16 | ||||||
Bone and colleagues [38] | 65/191 | 48/190 | 85/130 | 83/114 | 29/152 | 30/147 | NA | NA | NA | NA | ||||||
Luce and colleagues [46] | 22/38 | 20/37 | NA | NA | 3/38 | 4/37 | 18/38 | 16/37 | 16/38 | 15/37 | ||||||
Bollaert and colleagues [37]## | 7/22 | 12/19 | 15/22 | 4/23 | 18/22 | 11/19 | 12/18 | 2/11 | 3/4 | 2/8 | 7/22 | 9/19 | 1/22 | 3/19 | 3/22 | 3/19 |
Briegel and colleagues [39] | 5/20 | 6/20 | 18/20 | 16/20 | NA | NA | NA | NA | NA | NA | 10/20 | 7/20 | 1/20 | 0/20 | NA | NA |
Chawla and colleagues [47]# | 6/23 | 10/21 | 16/23 | 7/21 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Yildiz and colleagues [45] | 8/20 | 12/20 | NA | NA | 15/20 | 11/20 | NA | NA | NA | NA | 0/20 | 1/20 | NA | NA | 0/20 | 0/20 |
Annane and colleagues [36] | 95/160 | 103/150 | 60/151 | 40/149 | 36/150 | 34/149 | 18/36 | 18/34 | 65/114 | 46/115 | 22/150 | 27/150 | 11/150 | 8/149 | NA | NA |
Tandan and colleagues [44] | 11/14 | 13/14 | 5/14 | 3/14 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Oppert and colleagues [42] | 7/18 | 11/23 | 13/18 | 18/23 | 6/18 | 9/23 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Sprung and colleagues [8] | 111/251 | 100/245 | 200/251 | 184/248 | 118/243 | 136/244 | 100/118 | 104/136 | 98/125 | 76/108 | 78/234 | 61/132 | 15/234 | 13/232 | 186/234 | 161/232 |
Mortality outcome
Outcome | N | OR (95%CrI) | P(%) | τ (95%CrI) | β (95%CrI) | Pβ(%) | |
---|---|---|---|---|---|---|---|
Mortality
| |||||||
High dose | 5 | 0.912 (0.313 to 1.253) | 42.0 | 1.00 (0.42 to 1.89) | |||
High dose excluding Schumer [31] | 4 | 1.406 (0.727 to 2.614) | 89.3 | 0.25 (0.01 to 1.40) | |||
Low dose | 9 | 0.796 (0.396 to 1.386) | 20.4 | 0.65 (0.23 to 1.44) | |||
Low dose excluding CSG [32] | 8 | 0.706 (0.371 to 1.096) | 5.8 | 0.39 (0.04 to 1.15) | |||
Corticotrophin responders* | 4 | 0.882 (0.285 to 2.073) | 36.4 | 0.49 (0.02 to 1.78) | |||
Corticotrophin non-responders* | 4 | 0.831 (0.334 to 1.971) | 28.0 | 0.43 (0.02 to 1.69) | |||
Shock-reversal
| |||||||
High dose | 2 | 1.078 (0.227 to 6.311) | 54.9 | 1.39 (0.06 to 1.93) | |||
Low dose | 7 | 1.999 (1.069 to 4.55) | 98.2 | 0.57 (0.04 to 1.62) | |||
Corticotrophin responders* | 3 | 1.830 (0.499 to 7.845) | 86.7 | 0.87 (0.05 to -1.92) | |||
Corticotrophin non-responders* | 3 | 1.845 (0.637 to 7.267) | 91.9 | 0.55 (0.02 to 1.86) | |||
Meta-regression (log odds mortality)
| |||||||
Average age | High dose | 4 | 0.777 (0.285 to 2.426) | 27.3 | 0.72 (0.04 to 1.87) | 0.60 (-0.23 to 1.51) | 94.52 |
Excl Schumer [31] | 3 | 1.390 (0.399 to 4.872) | 77.0 | 0.66 (0.03 to 1.90) | 0.10 (-1.57 to 1.74) | 58.05 | |
Low dose | 6 | 0.658 (0.334 to 1.223) | 7.6 | 0.36 (0.02 to 1.51) | 0.05 (-0.10 to 0.18) | 80.53 | |
Underlying risk | High dose | 5 | 0.943 (0.292 to 3.049) | 45.4 | 1.14 (0.46 to 1.49) | 0.23 (-1.71 to 2.58) | 60.98 |
Excl Schumer [31] | 4 | 1.372 (0.596 to 3.249) | 82.9 | 0.38 (0.01 to 1.74) | -0.09 (-1.31 to 1.42) | 41.47 | |
Low dose | 9 | 0.752 (0.389 to 1.291) | 14.5 | 0.57 (0.17 to 1.37) | -0.49 (-1.14 to 0.27) | 7.80 | |
Excl CSG [32] | 8 | 0.676 (0.347 to 1.076) | 4.9 | 0.40 (0.03 to 1.23) | -0.28 (-0.88 to 0.50) | 19.08 | |
Odds of the following complications (corticosteroids versus control)
| |||||||
Superinfection | High dose | 4 | 1.127 (0.364 to 3.924) | 62.2 | 0.55 (0.02 to 2.85) | ||
Low dose | 6 | 0.955 (0.388 to 1.749) | 43.6 | 0.46 (0.03 to 1.62) | |||
GI bleeding | High dose | 3 | 0.824 (0.167 to 3.186) | 37.3 | 0.74 (0.03 to 1.90) | ||
Low dose | 5 | 1.103 (0.379 to 3.031) | 59.6 | 0.58 (0.02 to 1.84) | |||
Hyperglycemia | High dose | 3 | 1.012 (0.244 to 4.266) | 50.8 | 0.64 (0.03 to 1.88) | ||
Low dose | 3 | 1.430 (0.155 to 3.985) | 57.4 | 0.87 (0.05 to 1.93) |
Shock reversal
Metaregression
Complications of therapy
Heuristics
Discussion
Critique of methodology
Conclusions
Key messages
-
The efficacy of corticosteroids in patients with severe sepsis and septic shock is uncertain despite recent meta-analytic reviews.
-
Bayesian methods are apposite to express uncertainty in efficacy estimates from meta-analyses.
-
The efficacy of low-dose corticosteroids had a high probability of dependence upon patient age and underlying risk; low-dose steroid efficacy was not demonstrated in corticotrophin non-responders.
-
Bayesian meta-analytic predictive estimates were unable to suggest efficacy for future large trials.
-
A null effect for mortality treatment efficacy of low-dose corticosteroid therapy in severe sepsis and septic shock could not be excluded.